AN2 Therapeutics (ANTX) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Sol-Gel Technologies (SLGL) over the past year, gaining 366.1% versus a gain of 50.5%. AN2 Therapeutics is the larger company by market cap ($192.8 million vs $180.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | SLGL |
|---|---|---|
| Share price | $5.08 | $55.17 |
| Market cap | $192.75M | $180.63M |
| 1-day change | -2.68% | +2.02% |
| YTD return | +345.61% | +30.92% |
| 1-year return | +366.06% | +50.53% |
| 5-year return | — | -28.44% |
| EPS (TTM) | $-0.91 | $-5.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $19.39M |
| Revenue growth (YoY) | — | +68.04% |
| Net income (latest FY) | $-35.17M | $-6.13M |
| Operating margin | — | -38.88% |
| Net margin | — | -31.60% |
| 52-week high | $7.19 | $97.97 |
| 52-week low | $1.00 | $34.47 |
| Distance from 52-week high | -29.35% | -43.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.17% | +181.86% |
| Average volume | 289.29K | 47.38K |
| Shares outstanding | 37.94M | 3.27M |
| Employees | 21 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed SLGL by 315.5 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
ANTX vs SLGL FAQ
Which is bigger, AN2 Therapeutics or Sol-Gel Technologies?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $192.75M compared with $180.63M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, ANTX or SLGL?
ANTX returned +366.06% over the past 12 months, compared with +50.53% for SLGL (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.